Published in:
Open Access
01-08-2014 | Brief Report
A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe
Authors:
A. Mocroft, P. Reiss, A. Rakhmanova, D. Banhegyi, A. N. Phillips, S. De Wit, M. Ristola, J. D. Lundgren, J. Grarup, O. Kirk, for EuroSIDA in EuroCOORD
Published in:
Infection
|
Issue 4/2014
Login to get access
Abstract
ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.